BioDelivery Sciences International(NASDAQ:BDSI) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $5.00M. Analysts estimated a revenue of $3.35M. Earnings per share were $-0.31. Analysts had estimated an EPS of $-0.31.
BioDelivery Sciences International (BDSI) shares turned negative on Wednesdays trading session with the shares closing down -0.08 points or -2.81% at a volume of 4,42,757. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $2.84. The peak price level was also seen at $2.84 while the days lowest was $2.75. Finally the shares closed at $2.77. The 52-week high of the shares is $7.79 while the 52-week low is $1.86. According to the latest information available, the market cap of the company is $149 M.
Several Insider Transactions has been reported to the SEC. On Mar 23, 2016, Charles Bramlage (director) purchased 8,850 shares at $2.82 per share price.Also, On Mar 22, 2016, Niraj Vasisht (Chief Technology Officer) purchased 1,000 shares at $2.80 per share price.On Mar 22, 2016, Barry I Feinberg (director) purchased 10,000 shares at $2.74 per share price, according to the Form-4 filing with the securities and exchange commission.
BioDelivery Sciences International Inc. is a specialty pharmaceutical company. The Company develops and commercializes either on its own or in partnerships with third parties applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology a small erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product ONSOLIS (fentanyl buccal soluble film) as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate BELBUCA utilize its BEMA technology.